Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice

Cell

Volumn 166, Issue 6, 2016, Pages 1445-1458.e12

  Escolano, Amelia ^a   Steichen, Jon M ^a   Dosenovic, Pia ^a   Kulp, Daniel W ^a   Golijanin, Jovana ^a   Sok, Devin ^a,b   Freund, Natalia T ^a   Gitlin, Alexander D ^a   Oliveira, Thiago ^a   Araki, Tatsuya ^a   Lowe, Sarina ^a   Chen, Spencer T ^a   Heinemann, Jennifer ^a   Yao, Kai Hui ^a   Georgeson, Erik ^a   Saye Francisco, Karen L ^a   Gazumyan, Anna ^a   Adachi, Yumiko ^a   Kubitz, Michael ^a   Burton, Dennis R ^a,c   Schief, William R ^a,c   Nussenzweig, Michel C ^a,d   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PGT 121 ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; PRIMER DNA; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; FEMALE; GERMLINE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENTIAL IMMUNIZATION; SOMATIC MUTATION; VIRUS NEUTRALIZATION; VIRUS SPIKE; AMINO ACID SEQUENCE; ANIMAL; B LYMPHOCYTE; CHEMISTRY; GENE TARGETING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUTATION; SEQUENCE ALIGNMENT;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; B-LYMPHOCYTES; CLONING, MOLECULAR; DNA PRIMERS; EPITOPES; GENE KNOCK-IN TECHNIQUES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNIZATION; IMMUNOGLOBULINS; MICE; MUTATION; SEQUENCE ALIGNMENT;

EID: 84986313440     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.07.030     Document Type: Article

References (82)

1. Andrabi, R., Voss, J.E., Liang, C.H., Briney, B., McCoy, L.E., Wu, C.Y., Wong, C.H., Poignard, P., Burton, D.R., Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43 (2015), 959–973.
2. Baumjohann, D., Preite, S., Reboldi, A., Ronchi, F., Ansel, K.M., Lanzavecchia, A., Sallusto, F., Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38 (2013), 596–605.
3. Bhiman, J.N., Anthony, C., Doria-Rose, N.A., Karimanzira, O., Schramm, C.A., Khoza, T., Kitchin, D., Botha, G., Gorman, J., Garrett, N.J., et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21 (2015), 1332–1336.
4. Bonsignori, M., Hwang, K.K., Chen, X., Tsao, C.Y., Morris, L., Gray, E., Marshall, D.J., Crump, J.A., Kapiga, S.H., Sam, N.E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85 (2011), 9998–10009.
5. Burton, D.R., Hangartner, L., Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34 (2016), 635–659.
6. Burton, D.R., Desrosiers, R.C., Doms, R.W., Koff, W.C., Kwong, P.D., Moore, J.P., Nabel, G.J., Sodroski, J., Wilson, I.A., Wyatt, R.T., HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004), 233–236.
7. Cohen, Y.Z., Dolin, R., Novel HIV vaccine strategies: overview and perspective. Ther. Adv. Vaccines 1 (2013), 99–112.
8. Dimitrov, D.S., Therapeutic antibodies, vaccines and antibodyomes. MAbs 2 (2010), 347–356.
9. Doria-Rose, N.A., Schramm, C.A., Gorman, J., Moore, P.L., Bhiman, J.N., DeKosky, B.J., Ernandes, M.J., Georgiev, I.S., Kim, H.J., Pancera, M., et al., NISC Comparative Sequencing Program. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
10. Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N.T., Gitlin, A.D., McGuire, A.T., Kulp, D.W., Oliveira, T., Scharf, L., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161 (2015), 1505–1515.
11. Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H., Makizumi, K., et al. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J. Virol. 80 (2006), 5552–5562.
12. Foote, J., Eisen, H.N., Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92 (1995), 1254–1256.
13. Garces, F., Sok, D., Kong, L., McBride, R., Kim, H.J., Saye-Francisco, K.F., Julien, J.P., Hua, Y., Cupo, A., Moore, J.P., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159 (2014), 69–79.
14. Garces, F., Lee, J.H., de Val, N., de la Pena, A.T., Kong, L., Puchades, C., Hua, Y., Stanfield, R.L., Burton, D.R., Moore, J.P., et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43 (2015), 1053–1063.
15. Gautam, R., Nishimura, Y., Pegu, A., Nason, M.C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533 (2016), 105–109.
16. González-Fernández, A., Milstein, C., Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology 93 (1998), 149–153.
17. Goodnow, C.C., Vinuesa, C.G., Randall, K.L., Mackay, F., Brink, R., Control systems and decision making for antibody production. Nat. Immunol. 11 (2010), 681–688.
18. Gorman, J., Soto, C., Yang, M.M., Davenport, T.M., Guttman, M., Bailer, R.T., Chambers, M., Chuang, G.Y., DeKosky, B.J., Doria-Rose, N.A., et al., NISC Comparative Sequencing Program. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23 (2016), 81–90.
19. Gray, E.S., Madiga, M.C., Hermanus, T., Moore, P.L., Wibmer, C.K., Tumba, N.L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al., CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85 (2011), 4828–4840.
20. Gruell, H., Bournazos, S., Ravetch, J.V., Ploss, A., Nussenzweig, M.C., Pietzsch, J., Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J. Virol. 87 (2013), 8535–8544.
21. Haynes, B.F., Montefiori, D.C., Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5 (2006), 347–363.
22. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B., B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30 (2012), 423–433.
23. Hoot, S., McGuire, A.T., Cohen, K.W., Strong, R.K., Hangartner, L., Klein, F., Diskin, R., Scheid, J.F., Sather, D.N., Burton, D.R., Stamatatos, L., Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog., 9, 2013, e1003106.
24. Hraber, P., Seaman, M.S., Bailer, R.T., Mascola, J.R., Montefiori, D.C., Korber, B.T., Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28 (2014), 163–169.
25. Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
26. Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog, P.D., Thinnes, T.C., Bhullar, D., Briney, B., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349 (2015), 156–161.
27. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
28. Julien, J.P., Sok, D., Khayat, R., Lee, J.H., Doores, K.J., Walker, L.M., Ramos, A., Diwanji, D.C., Pejchal, R., Cupo, A., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog., 9, 2013, e1003342.
29. Kepler, T.B., Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res., 2, 2013, 103.
30. Kepler, T.B., Liao, H.X., Alam, S.M., Bhaskarabhatla, R., Zhang, R., Yandava, C., Stewart, S., Anasti, K., Kelsoe, G., Parks, R., et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16 (2014), 304–313.
31. Klein, F., Halper-Stromberg, A., Horwitz, J.A., Gruell, H., Scheid, J.F., Bournazos, S., Mouquet, H., Spatz, L.A., Diskin, R., Abadir, A., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492 (2012), 118–122.
32. Klein, F., Diskin, R., Scheid, J.F., Gaebler, C., Mouquet, H., Georgiev, I.S., Pancera, M., Zhou, T., Incesu, R.B., Fu, B.Z., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153 (2013), 126–138.
33. Klein, F., Mouquet, H., Dosenovic, P., Scheid, J.F., Scharf, L., Nussenzweig, M.C., Antibodies in HIV-1 vaccine development and therapy. Science 341 (2013), 1199–1204.
34. Klein, F., Nogueira, L., Nishimura, Y., Phad, G., West, A.P. Jr., Halper-Stromberg, A., Horwitz, J.A., Gazumyan, A., Liu, C., Eisenreich, T.R., et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211 (2014), 2361–2372.
35. Klinman, D.M., Higgins, K.W., Conover, J., Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells. J. Exp. Med. 173 (1991), 881–887.
36. Kong, L., Lee, J.H., Doores, K.J., Murin, C.D., Julien, J.P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20 (2013), 796–803.
37. Kwong, P.D., Doyle, M.L., Casper, D.J., Cicala, C., Leavitt, S.A., Majeed, S., Steenbeke, T.D., Venturi, M., Chaiken, I., Fung, M., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002), 678–682.
38. Kwong, P.D., Mascola, J.R., Nabel, G.J., Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13 (2013), 693–701.
39. Li, M.Z., Elledge, S.J., Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat. Methods 4 (2007), 251–256.
40. Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
41. Malherbe, D.C., Doria-Rose, N.A., Misher, L., Beckett, T., Puryear, W.B., Schuman, J.T., Kraft, Z., O'Malley, J., Mori, M., Srivastava, I., et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85 (2011), 5262–5274.
42. Mascola, J.R., Haynes, B.F., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254 (2013), 225–244.
43. Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpenter, C.B., Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx, D.L., Lewis, M.G., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000), 207–210.
44. McCoy, L.E., Weiss, R.A., Neutralizing antibodies to HIV-1 induced by immunization. J. Exp. Med. 210 (2013), 209–223.
45. McGuire, A.T., Hoot, S., Dreyer, A.M., Lippy, A., Stuart, A., Cohen, K.W., Jardine, J., Menis, S., Scheid, J.F., West, A.P., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210 (2013), 655–663.
46. Mestas, J., Hughes, C.C.W., Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004), 2731–2738.
47. Moldt, B., Rakasz, E.G., Schultz, N., Chan-Hui, P.Y., Swiderek, K., Weisgrau, K.L., Piaskowski, S.M., Bergman, Z., Watkins, D.I., Poignard, P., Burton, D.R., Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109 (2012), 18921–18925.
48. Montefiori, D.C., Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol., Chapter 12, 2005 Unit 12.11.
49. Mouquet, H., Scheid, J.F., Zoller, M.J., Krogsgaard, M., Ott, R.G., Shukair, S., Artyomov, M.N., Pietzsch, J., Connors, M., Pereyra, F., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467 (2010), 591–595.
50. Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J.F., Halper-Stromberg, A., Gnanapragasam, P.N., Spencer, D.I., Seaman, M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109 (2012), E3268–E3277.
51. Pancera, M., McLellan, J.S., Wu, X., Zhu, J., Changela, A., Schmidt, S.D., Yang, Y., Zhou, T., Phogat, S., Mascola, J.R., Kwong, P.D., Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84 (2010), 8098–8110.
52. Pantaleo, G., Koup, R.A., Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10 (2004), 806–810.
53. Pavri, R., Nussenzweig, M.C., AID targeting in antibody diversity. Adv. Immunol. 110 (2011), 1–26.
54. Pelanda, R., Schwers, S., Sonoda, E., Torres, R.M., Nemazee, D., Rajewsky, K., Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 7 (1997), 765–775.
55. Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003), 4144–4149.
56. Sanders, R.W., Derking, R., Cupo, A., Julien, J.P., Yasmeen, A., de Val, N., Kim, H.J., Blattner, C., de la Peña, A.T., Korzun, J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog., 9, 2013, e1003618.
57. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
58. Scheid, J.F., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch, J., Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 (2009), 636–640.
59. Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
60. Schiffner, T., Sattentau, Q.J., Dorrell, L., Development of prophylactic vaccines against HIV-1. Retrovirology, 10, 2013, 72.
61. Schoofs, T., Klein, F., Braunschweig, M., Kreider, E.F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J.C., Parrish, E.H., Learn, G.H., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
62. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M.W., Martin, M.A., Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 (1999), 204–210.
63. Shih, T.A., Roederer, M., Nussenzweig, M.C., Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3 (2002), 399–406.
64. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M. Jr., Lifson, J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
65. Simonich, C.A., Williams, K.L., Verkerke, H.P., Williams, J.A., Nduati, R., Lee, K.K., Overbaugh, J., HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166 (2016), 77–87.
66. Sok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J.P., Briney, B., Ramos, A., Saye, K.F., Le, K., et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog., 9, 2013, e1003754.
67. Sok, D., Doores, K.J., Briney, B., Le, K.M., Saye-Francisco, K.L., Ramos, A., Kulp, D.W., Julien, J.P., Menis, S., Wickramasinghe, L., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med., 6, 2014, 236ra63.
68. Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity, 45, 2016, 10.1016/j.immuni.2016.08.016 Published online on September 8, 2016.
69. Stewart-Jones, G.B., Soto, C., Lemmin, T., Chuang, G.Y., Druz, A., Kong, R., Thomas, P.V., Wagh, K., Zhou, T., Behrens, A.J., et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165 (2016), 813–826.
70. Stills, H.F. Jr., Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46 (2005), 280–293.
71. Victora, G.D., Nussenzweig, M.C., Germinal centers. Annu. Rev. Immunol. 30 (2012), 429–457.
72. von Boehmer, L., Liu, C., Ackerman, S., Gitlin, A.D., Wang, Q., Gazumyan, A., Nussenzweig, M.C., Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat. Protoc., 2016, 10.1038/nprot.2016.102.
73. Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., et al., Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
74. Walker, L.M., Simek, M.D., Priddy, F., Gach, J.S., Wagner, D., Zwick, M.B., Phogat, S.K., Poignard, P., Burton, D.R., A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog., 6, 2010, e1001028.
75. Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P., Wang, S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al., Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477 (2011), 466–470.
76. Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
77. West, A.P. Jr., Scharf, L., Scheid, J.F., Klein, F., Bjorkman, P.J., Nussenzweig, M.C., Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156 (2014), 633–648.
78. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
79. Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., McKee, K., et al., NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 (2011), 1593–1602.
80. Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Kwon, Y.D., Zhou, T., Sheng, Z., Zhang, B., O'Dell, S., McKee, K., et al., NISC Comparative Sequencing Program. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell 161 (2015), 470–485.
81. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.Y., Longo, N.S., Dimitrov, D.S., Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390 (2009), 404–409.
82. Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 (2010), 811–817.